Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.
Mandate

Vinge advises NeuroNova AB in relation to the merger with Newron Pharmaceuticals S.p.A.

June 13, 2012

Vinge has advised NeuroNova AB in connection with the merger with Newron Pharmaceuticals S.p.A (”Newron”). NeuroNova AB is a research company within the biotechnology and pharmaceuticals industry which primarily develops therapies for illnesses caused by the death of cells in the central nervous system. Newron is a research company within biotechnology and is listed on the Swiss stock exchange (SIX).

Vinge’s team consisted of, among others, responsible partner Johan Winnerblad and associates Matthias Pannier and Alex Miler.

Related

Vinge advises the financing banks in connection with Verdane and Telenor’s partnership in Telenor Connexion

 Vinge has advised a syndicate of Nordic and Northern European banks connection with the financing of Verdane and Telenor’s new partnership relating to Telenor Connexion. Under the partnership, Verdane and Telenor will jointly invest in Telenor Connexion, a leading provider of IoT solutions. The transaction was completed on 10 September 2026 and values Telenor Connexion at SEK 7.5 billion.
September 23, 2026

Vinge advises Accru Partners on its EUR 550 million senior secured bond issuance

 Vinge advises Accru Partners, backed by Axcel, in connection with Accru Partners’ inaugural EUR 550 million issuance of senior secured bonds.
September 23, 2026

Vinge advises Sveafastigheter on EUR 350 million bond issuance

 Vinge has advised Sveafastigheter AB (publ) on the issuance of EUR 350 million in senior unsecured bonds under its existing EUR 2 billion EMTN programme.
September 23, 2026